Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Prepaid Assets (2023 - 2025)

Ascentage Pharma Group International posted quarterly Prepaid Assets of $27.1 million for Q4 2025, up 58.26% year-on-year from $17.2 million in Q4 2024, and up 21.3% on a QoQ basis from $22.4 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Prepaid Assets data on file, last reported at $27.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 58.26% year-over-year to $27.1 million; the trailing twelve-month figure through Dec 2025 stood at $27.1 million (up 58.26% YoY), and the FY2025 full-year result was $27.5 million, up 63.1% from the prior year.
  • Prepaid Assets for Q4 2025 stood at $27.1 million, up from $22.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $27.1 million in Q4 2025 and bottomed at $12.3 million in Q4 2023.
  • The 3-year median for Prepaid Assets is $19.8 million (2025), against an average of $19.7 million.
  • The widest annual swing landed in 2024, when Prepaid Assets soared 39.89%; it then soared 58.26% in 2025.
  • A 3-year view of Prepaid Assets shows it stood at $12.3 million in 2023, then soared by 39.89% to $17.2 million in 2024, then jumped by 58.26% to $27.1 million in 2025.
  • The last three Prepaid Assets figures came in at $27.1 million (Q4 2025), $22.4 million (Q2 2025), and $17.2 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 27.15 Mn
Jun 30, 2025 22.38 Mn
Dec 31, 2024 17.15 Mn
Dec 31, 2023 12.26 Mn